Loading stock data…
$0.96+0.00 (+0.17%)
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases.
FibroBiologics, Inc. in the Healthcare sector is trading at $0.96 with a market capitalization of $9M. Wall Street consensus targets $12.50 (2 analysts), implying a +1200.1% move over the next 12 months. The stock is currently near its 52-week low of $0.62, remaining 64.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.03M↑ | -$5.07M↓ | -$2.59M↑ | -$5.04M↓ | -$4.49M |
| Net Income | -$4.12M↑ | -$5.00M↓ | -$3.24M↑ | -$5.78M↓ | -$4.66M |
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has compl...